Epidemiological, clinical, and therapeutic aspects of primary intracerebral hemorrhage

Alfonso Ciccone, Mario Pozzi, Cristina Motto, Pietro Tiraboschi, Roberto Sterzi

Research output: Contribution to journalArticlepeer-review


Primary intracerebral hemorrhage is the least treatable form of stroke and is associated with high mortality rates. In the thrombolytic era, the attention has bee driven on the first hours of onset, when the hematoma is still growing. Intervention with ultra-early hemostatic therapy might arrest ongoing bleeding. Even if recombinant activated factor VII administered within 4 h of symptom onset did not improve outcome in a recent phase 3 trial, it reduced hematoma growth. Therefore, the rational for ultra-early hemostatic therapy it is still valid and another trial on hemostatic treatment is warranted.

Original languageEnglish
JournalNeurological Sciences
Issue numberSUPPL. 2
Publication statusPublished - Sep 2008


  • Hemostatic treatment
  • Primary intracerebral hemorrhage
  • Randomized controlled trial
  • Recombinant activated factor VII
  • Tranexamic acid

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology


Dive into the research topics of 'Epidemiological, clinical, and therapeutic aspects of primary intracerebral hemorrhage'. Together they form a unique fingerprint.

Cite this